BusinessFrance

Bioamber produces bio-based 1,4-butanediol on industrial scale

28.03.2012 - Bioamber Inc. is one step closer to the environmental summit. The company's goal is to establish sustainable, "green" chemistry on an industrial scale.

The French/US enterprise has now scaled up its hydrogenation catalyst technology for converting biologically produced succinic acid into 1,4-butanediol (1,4-BDO), tetrahydrofuran (THF) and gamma-butyrolactone (GBL). These bulk chemicals are needed for making polyesters, polyurethanes, spandex and biodegradable plastics. The global addressable market for these products exceeds $4bn, according to BioAmber, with an annual market for 1,4-BDO alone of 1.3m tons. Bio-succinate has being produced since 2010 near Reims in a huge 350,000L fermenter from corn. Other production sites are planned for Canada (Sarnia, Ontario) and Thailand. According to Chief Technology Officer Jim Millis, Bioamber "is developing an integrated plant engineering design that combines the production of bio-succinic acid and bio-based 1,4-BDO on a single site". So far bio-succinate comes from Bioamber S.A.S's factory in France (Banzancourt/Pomacle). The endeavour to refine succinate into 1,4-BDO was undertaken together with DuPont (USA) which is one of the world's leading commercial catalyst suppliers. After successfully having established industrial C4-chemistry based on renewable resources, Bioamber is in the process of producing a C6-molecule (adipic acid), also in a sustainable manner. However, industrial production is not anticipated to start before 2015.

http://www.european-biotechnology-news.com/news/business/2012-01/bioamber-produces-bio-based-14-butanediol-on-industrial-scale.html

PoliticsEUPolandItalySpainUK

16.12.2014 Two consortia combined of 144 European companies, research institutes and universities have been selected for funding by the EIT in the areas of health and raw materials. Both clusters are set to acquire €1.1bn over the next seven years.

M&ALuxembourg

11.12.2014 Luxembourg bio-analytical testing company Eurofins Scientific has signed an agreement to acquire Boston Heart Diagnostics Corp. for an initial €112m.

StudySwitzerlandEU

10.12.2014 When it comes to the biggest investors in Research and Development (R&D) Swiss pharma top dogs Novartis and Roche have defended their positioning among the top ten companies worldwide – according to a recently published EU study.

FinancingUKSpain

09.12.2014 British drug delivery specialist Midatech Pharma plc floated on the London stock market. It is the third biotech IPO on the AIM market this year.

CooperationAustria

05.12.2014 Austrian contract research company VTU has entered into a development and commercialisation agreement with US company RCT. The partners want to combine both companies' Pichia pastoris protein production technologies under VTU's roof.

FinancingDenmark

03.12.2014 Danish biotech pharma Ascendis has successfully completed a €48m Series D financing round. The funding is expected to support its late-stage clinical trials to push its lead drug into Phase III trials.

RegulationUKFranceGermanySpain

01.12.2014 In spite of innovative new medicines on the market, the UK and Germany lag behind other countries and continue to use older medicines - especially in the treatment of cancer. French and Spanish patients, on the other hand, benefit much earlier from medical innovation.

RegulationItalyGermanyNetherlandsEU

28.11.2014 The first gene therapy for a rare genetic condition — UniQure's Glybera — is on its way to the European market. But there is a hefty price tag: Chiesi, responsible for the marketing of the orphan drug, is asking for a record price of €1.1m per patient.

Events

All Events

Current issue

All issues

Product of the week

Products